Holen Sie sich die Stockscreener-App
56.39
0.45%
0.25
Handel nachbörslich:
56.39
Schlusskurs vom Vortag:
$56.14
Offen:
$56.38
24-Stunden-Volumen:
386.60K
Relative Volume:
0.64
Marktkapitalisierung:
$2.18B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.99M
KGV:
-18.61
EPS:
-3.03
Netto-Cashflow:
$-24.94M
1W Leistung:
+0.18%
1M Leistung:
+13.62%
6M Leistung:
+24.98%
1J Leistung:
+143.27%
1-Tages-Spanne:
$55.64
$56.73
1-Wochen-Bereich:
$54.10
$56.73
52-Wochen-Spanne:
$21.30
$57.28
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Firmenname
Soleno Therapeutics Inc
Sektor
Branche
Telefon
650-213-8444
Adresse
203 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-23 | Eingeleitet | Stifel | Buy |
| 2023-11-21 | Fortgesetzt | Guggenheim | Buy |
| 2020-09-29 | Eingeleitet | Guggenheim | Buy |
| 2020-01-10 | Eingeleitet | Craig Hallum | Buy |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
(SLNO) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Brokerages Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) Target Price at $69.86 - Defense World
Emerald Advisers LLC Grows Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $73.00 at Oppenheimer - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Hits New 52-Week High Following Analyst Upgrade - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stake Boosted by Allspring Global Investments Holdings LLC - Defense World
Capnia Inc stock soars to 52-week high of $56.89 amid robust growth By Investing.com - Investing.com South Africa
Soleno Therapeutics shares remain Outperform as analyst lifts price target on updated sales projections - Investing.com Australia
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Capnia Inc stock soars to 52-week high of $56.89 amid robust growth - Investing.com India
Oppenheimer Boosts Soleno Therapeutics (NASDAQ:SLNO) Price Target to $73.00 - MarketBeat
Soleno Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewswire
(SLNO) Technical Data - Stock Traders Daily
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D. - GlobeNewswire
TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors - Barron's
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA - MSN
Prader-Willi Syndrome Market to Drive Growth with Prominent - openPR
Soleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCR - Insider Monkey
Soleno Therapeutics Inc (SLNO)’s stock price in review: A technical analysis - US Post News
Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment - Insider Monkey
The Potential Rise in the Price of Soleno Therapeutics Inc (SLNO) following insiders activity - Knox Daily
Soleno Therapeutics (NASDAQ:SLNO) Trading Up 6.4%Time to Buy? - MarketBeat
Insider’s View: Deciphering Soleno Therapeutics Inc (SLNO)’s Financial Health Through Ratios - The Dwinnex
Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc. - GuruFocus.com
Taking a look at what insiders are doing to gauge the Soleno Therapeutics Inc (SLNO)’s direction - Knox Daily
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments - Seeking Alpha
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Holdings Lifted by The Manufacturers Life Insurance Company - MarketBeat
Soleno Therapeutics Inc [SLNO] Revenue clocked in at $0.00 million, up 29.12% YTD: What’s Next? - The DBT News
Recent Price Trend in Soleno Therapeutics (SLNO) is Your Friend, Here's Why - Yahoo Canada Finance
Belite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On Oculis - RTTNews
FDA leans away from advisory meeting for Soleno's PWS drug By Investing.com - Investing.com South Africa
Laidlaw maintains buy rating, $75 target on Soleno Therapeutics By Investing.com - Investing.com Australia
Soleno shares set to surge on positive FDA update - Investing.com India
Capnia Inc stock soars to 52-week high, hits $56.14 - Investing.com
Stifel maintains Buy rating on Soleno Therapeutics shares - Investing.com
Baird reiterates price target on Soleno shares, positive on FDA update - Investing.com
Why Soleno Therapeutics Stock Blasted 9% Higher Today - Yahoo Finance
Baird reiterates price target on Soleno shares, positive on FDA update By Investing.com - Investing.com South Africa
Capnia Inc stock soars to 52-week high, hits $56.14 By Investing.com - Investing.com South Africa
Laidlaw maintains buy rating, $75 target on Soleno Therapeutics - Investing.com
Anchoring Your Portfolio: Is SLNO Stock a Safe Harbor? - The InvestChronicle
A look at SLNO’s current quarter earnings estimates - US Post News
Stifel maintains Buy rating on Soleno Therapeutics shares By Investing.com - Investing.com Australia
Soleno shares set to surge on positive FDA update By Investing.com - Investing.com Australia
Stock Traders Purchase High Volume of Soleno Therapeutics Put Options (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics's Options Frenzy: What You Need to Know - Benzinga
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year HighHere's What Happened - MarketBeat
FDA Regulatory News Sends Soleno Therapeutics (SLNO) Shares Higher - Stocks Telegraph
Finanzdaten der Soleno Therapeutics Inc-Aktie (SLNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):